Despite Just-In-Time (JIT) production often being the preferred approach in clinical trial supply, it has taken a global pandemic for many organizations to make it a reality. Now, as we look to the future, PRISYM ID’s Bob Bowdish explains why these practices may be here to stay.
In the last 2 years, and accelerated by Covid, native advertising has exploded across healthcare for DTC and HCP marketing. Native ads have been adopted by all healthcare industries including pharma, device, health systems, retailers, pharmacies, payers, and the gamut of regional service providers. But there are still a handful of advertiser holdouts, and they are missing out on highly engaged audiences.